Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies

Executive Summary

Adlai Nortye licensed exclusive worldwide development and commercialization rights to Novartis Pharma AG's buparlisib (BKM120) for all therapeutic, prophylactic, or diagnostic uses, except for certain rights Novartis retains.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register